Morning Brew - 🧬 Biotech breakthrough

TOGETHER WITH

As the world’s population ages, biotech companies are under pressure to make advances in regenerative treatments for debilitating diseases.

One that’s top of mind for many researchers? Osteoarthritis (OA). This disease, which erodes the protective cartilage within joints and causes severe pain, will affect 25% of the adult population by 2030.

There was no way to stop its progression—until Cytonics developed the first and only therapy that targets the disease at its root.

We’re not talking about a painkiller or a symptom-management strategy. It’s a straight-up disease-modifying treatment. And you have the opportunity to become a shareholder in this breakthrough today.

Learn more

Cytonics has already seen proven success in regenerative medicine. They’ve commercialized an FDA-approved medical device for OA that’s successfully treated 8,000 patients. And while it was a clinical and commercial success, there is still room for improvement.

With their next-gen OA treatment, known as CYT-108, Cytonics is taking critical steps to bring a first-of-its kind treatment to a $240b market. This therapy is even more effective for patients thanks to these advancements:

It can be produced en masse and sold globally (read: cost-effective).
It will be available “off the shelf” for immediate use (no lengthy doctor’s visit needed).
It’s more likely to be covered by insurance (it’s a biopharmaceutical vs. a device).

The company is already backed by Johnson & Johnson and the National Institutes of Health. And with 22 issued and 5 pending patents, they’re making steady progress to get their game-changing biotech to the joints of 600m people (and counting) and provide a better quality of life.

Cytonics is currently conducting an equity crowdfunding investment round ahead of their next growth milestone, phase 1 human clinical trials, so it’s not too late to become a shareholder in this biotech breakthrough before they enter the clinic.

Cheers,

☕️ The Brew Crew

This paid content was created with our sponsor and does not necessarily reflect the opinions or point of view of Emerging Tech Brew.

Disclosure: In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained here.

Emerging Tech Brew is a product of Morning Brew // 22 W 19th St, 4th Floor, New York, NY 10011.

You were sent this message because you opted-in and subscribed to Emerging Tech Brew. If you believe this has been sent to you in error, you can safely ignore it. To stop getting emails like this, click here.

Key phrases

equity crowdfunding investment round Emerging Tech Brew straightup diseasemodifying treatment next growth milestone The Brew Crew gen OA treatment

Older messages

☕ Birkin battle

Tuesday, January 31, 2023

Why there's a big fight brewing over digital purses... January 31, 2023 View Online | Sign Up | Shop 10% Off Morning Brew TOGETHER WITH RAD Diversified Good morning. The slow, lumbering migration

☕ Reality check

Monday, January 30, 2023

Sustainability in the metaverse vs. real life. January 30, 2023 Retail Brew TOGETHER WITH Yelp It's Monday, and just 15 days until Valentine's Day. If you're unattached, some good news.

☕ Period of reckoning

Monday, January 30, 2023

Tech hiring has nearly dropped to pre-pandemic levels. January 30, 2023 Emerging Tech Brew Welcome to the week. It's a big one for this here newsletter. For nearly four years, you've known us

☕ Please don’t go

Monday, January 30, 2023

Making the most of fewer ad dollars. January 30, 2023 Marketing Brew TOGETHER WITH Impact.com It's Monday. Marketers like you perform best when you know everything about the business. The Brew will

☕ Happy 30th

Monday, January 30, 2023

Plus, the mystery of a missing radioactive capsule... January 30, 2023 View Online | Sign Up | Shop 10% Off Morning Brew TOGETHER WITH CardCritics Good morning. Scratch that, great morning because the

The Honey Trap

Thursday, March 23, 2023

The FBI used an undercover cop with pink hair to spy on activists and manufacture crimes. MOST READ The FBI Used an Undercover Cop With Pink Hair to Spy on Activists and Manufacture Crimes Trevor

TikTok, Organ Transplant Overhaul, and Allergy Hotspots

Thursday, March 23, 2023

Facts, without motives. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

A Betrayal Lets Big Pharma Profiteer Off Cancer Drug

Thursday, March 23, 2023

Rejecting cancer patients' petition, the Biden administration refuses to use the power its HHS Secretary demanded Trump use. A Betrayal Lets Big Pharma Profiteer Off Cancer Drug By The Lever • 23

Say your piece

Thursday, March 23, 2023

It's been a busy month for Popular Information. Here are a few highlights from our reporting over the last 30 days: Popular Information authorit… ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

☕ We don't <3

Thursday, March 23, 2023

The Supreme Court considers a dog poop joke... March 23, 2023 View Online | Sign Up | Shop 10% Off Morning Brew SPONSORED BY tastytrade Good morning. It's a big day: TikTok's CEO is testifying

Numlock News: March 23, 2023 • Gladiators, Oreos, Dolphins

Thursday, March 23, 2023

By Walt Hickey Fraud A Massachusetts man was sentenced to four and a half years in prison after pleading guilty to running a sophisticated romance fraud scheme from 2016 to 2020. Targeting mostly older

Supreme Court weighs trademarks - Organ transplant reform - 3D-printed food

Thursday, March 23, 2023

Fed interest rate hike • Uganda anti-gay bill • Supreme Court trademark case • 3D-printed cake • Organ transplant reform • 23 MAR 2023 View in browser The Factual Facts, not fear. TRENDING TOPICS Fed

SpaceX tries to de-orbit Amazon's request for a satellite broadband shortcut [Thu Mar 23 2023]

Thursday, March 23, 2023

Hi The Register Subscriber | Log in The Register {* Daily Headlines *} 23 March 2023 satellite SpaceX tries to de-orbit Amazon's request for a satellite broadband shortcut Stop the presses:

Creator funds are even more bullshit than we realized

Thursday, March 23, 2023

PLUS: How Matt Navarra turned his marketing newsletter into a six-figure business ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

What A Day: D.A.-break

Thursday, March 23, 2023

We're getting whiplash with all of these legal updates someone please indict this man already. Wednesday, March 22, 2023 BY JULIA CLAIRE & CROOKED MEDIA - Rep. John Joyce (R-PA) describing